Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GSK1605786A in Moderately-to-Severely Active Crohn's Disease
2010-022382-10Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing GSK1605786A with Placebo (2 arms). Primary endpoint: Clinical response at Week 12. Started Oct 2010; status: completed.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-022382-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022382-10.